Publications found:
71,834
Sort by:
Germany Data for Surgeries: Procedure Data and Forecast, 2016-2023
US$ 1,500.00
... drive the growth of surgical procedures performed in Germany. Key Segments: By Surgery Hip implants surgeries Major peritoneal surgeries Thoracic surgeries CNS surgery ENT Surgeries By Hospitalization (provided for each ...
February 2018
30 pages
Stethoscopes: Market Research Report
US$ 5,600.00
... worldwide markets for Stethoscopes in US$ Thousand by the following Product Segments: Manual and Mechanical Stethoscopes, Electronic Stethoscopes, Esophageal Stethoscopes, Fetal Stethoscopes, and ... six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and ...
January 2018
252 pages
Testosterone Replacement Therapy (TRT): Market Research Report
US$ 5,600.00
This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and US markets are further analyzed by the following Product Segments: ... , a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary ...
January 2018
203 pages
Fibromyalgia Therapeutics: Market Research Report
US$ 5,450.00
This report analyzes the Global market for Fibromyalgia Therapeutics in US$ Million. Annual estimates and forecasts are provided for the ... 2022. Also, a six-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary ...
January 2018
78 pages
Acute Myeloid Leukemia (AML) Therapeutics: Market Research Report
US$ 5,450.00
This report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the ... players such as - Bayer AG Bristol-Myers Squibb Company Cardiorentis AG CVie Therapeutics Limited Cytokinetics, Inc.
January 2018
156 pages
Whey Protein Ingredients: Market Research Report
US$ 5,600.00
This report analyzes the worldwide markets for Whey Protein Ingredients in Thousand Pounds (lbs.). The report provides separate comprehensive analytics ... many key and niche players such as - Arla Foods Ingredients Group P/S Amco Proteins Carbery Food Ingredients Cargill, Inc. Dairy Farmers of America, Inc.
January 2018
281 pages
Targeted Therapies in Asthma: KOL Insight [2018]
US$ 8,495.00
... how developers can differentiate their pipeline therapies in KOL Insight: Targeted Therapies in Asthma. Ten North American and European KOLs provide their insight on 3 marketed products and ...
January 2018
-
NPS+ Renal Cell Carcinoma (EU5) 2018
US$ 2,655.00
... more than others? There are various options available to EU5 oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greater ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by answering ...
January 2018
-
NPS+ Renal Cell Carcinoma (US) 2018
US$ 2,655.00
... than others? There are various options available to US oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greater levels ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by answering ...
January 2018
-
NPS+ HIV (EU5) 2018
US$ 2,655.00
... how does each of the leading brands compare to its competitors? NPS+ HIV (EU5) gives a unique insight into the overall brand health of 11 leading ... in the world.We conducted the survey between February 6-14, 2018. What is Net Promoter® Score? NPS is a customer loyalty metric developed by (and a registered ...
January 2018
-
NPS+ HIV (US) 2018
US$ 2,655.00
... is ‘useful but very expensive’? Explore Important Brand Loyalty Issues NPS+ HIV (US) offers valuable insight into brand loyalty from the perspective ... in the world.We conducted the survey between February 6-14, 2018. What is Net Promoter® Score? NPS is a customer loyalty metric developed by (and a registered ...
January 2018
-
Market Access Impact: Psoriasis (US) 2018
US$ 5,345.00
... your brand can do to level the playing field in Market Access Impact: Psoriasis (US) [2018]. Based on a survey of 100 dermatologists ... Market Access Barriers Market Access Impact: Psoriasis (US) explores key issues affecting Psoriasis drug manufacturers. You’ll learn: How barriers affect market access: ...
January 2018
-
Market Access Impact: Psoriasis (EU5) 2018
US$ 5,345.00
... help the last place brand double its share in Market Access Impact: Psoriasis (EU5) [2018]. Based on a survey of 150 ... Exploring Market Access Barriers Market Access Impact: Psoriasis (EU5) explores key issues affecting Psoriasis drug manufacturers. You’ll learn: How barriers affect market access: What ...
January 2018
-
Global Epileptic Seizure Monitor Alarm System Market by Manufacturers, Countries, Type and Application, Forecast to 2023
US$ 3,480.00
... THE REPORT: This report focuses on the Epileptic Seizure Monitor Alarm System in global market, especially in North America, Europe, ... Chapters to deeply display the global Epileptic Seizure Monitor Alarm System market. Chapter 1, to describe Epileptic Seizure Monitor Alarm System Introduction, product scope, ...
January 2018
108 pages
Epiomic Epidemiology Series: Refractive Errors Forecast in 18 Major Markets 2018–2028
US$ 6,800.00
Black Swan Analysis Epiomic Epidemiology Forecast Report on Refractive Errors in 18 Major Markets The main role of the optical components of the ... eye to converge the refracted rays on the retina are known as refractive errors (ametropias). The report covers the features and epidemiology facts of hyperopia, ...
January 2018
148 pages
Epiomic Epidemiology Series: Uveitis Forecast in 18 Major Markets 2018–2028
US$ 5,800.00
Black Swan Analysis Epiomic Epidemiology Forecast Report on Uveitis in 18 Major Markets Uveitis is a general term denoting a group of inflammatory conditions of the ... a country level across the 10-year forecast snapshot. Main symptoms and co-morbidities of uveitis include: Autoimmune diseases (systemic) Ocular ...
January 2018
84 pages
Glioblastoma: KOL Insight
US$ 8,495.00
... the market? Learn how KOLs see the glioblastoma market evolving in Glioblastoma: KOL Insight (2018). Twelve US and European KOLs provide candid insights on 3marketed and 19 ... are overwhelmingly our first go-to option in the recurrent setting for glioblastoma patients. Again, we have a bunch of those that are ...
January 2018
-
Market Access Impact: Melanoma (EU5) 2018
US$ 5,345.00
... help the last place brand double its share in Market Access Impact: Melanoma (EU5) [2018]. Based on a survey of 150 oncologists ... (vemurafenib; Roche) Market Access Impact: Melanoma (EU5) explores key issues affecting Melanoma drug manufacturers. You’ll learn: How barriers affect market access: What brands do ...
January 2018
-
Market Access Impact: Melanoma (US) 2018
US$ 5,345.00
... what your brand can do to level the playing field in Market Access Impact: Melanoma (US) [2018]. Based on a survey of 100 oncologists and ... ; Roche) Market Access Impact: Melanoma (US) [2018] explores key issues affecting melanoma drug manufacturers. You’ll learn: How barriers affect market access: What brands ...
January 2018
-
Medical Affairs Reputations: Psoriasis (EU5) 2018
US$ 6,365.00
... stacks up to the market leader. In the EU5, several of the psoriasis medical affairs teams we surveyed are running neck and neck ... all the ways you can improve your medical affairs services in Medical Affairs Reputations: Psoriasis (EU5). Comparing 12 major Psoriasis treatments from AbbVie, Biogen, Celgene, ...
January 2018
-
Medical Affairs Reputations: Psoriasis (US) 2018
US$ 6,365.00
... come out on top? In the US, nearly all of the psoriasis medical affairs teams we surveyed are running neck and neck with at least ... all the ways you can improve your medical affairs services in Medical Affairs Reputations: Psoriasis (US). Comparing 11 major psoriasis treatments from AbbVie, Amgen, Celgene, Eli ...
January 2018
-
MSL Teams: Field force size and structure
US$ 1,495.00
... ? The answers to these and many other questions can be found in MSL Teams: Field Force Size and Structure. This extensive market survey reveals the insights ...
January 2018
-
NPS+ Hepatitis C Virus (HCV) Infection US [2018]
US$ 2,655.00
... to US infectious diseases specialists and primary care physicians (PCPs) treating hepatitis C virus infection (HCV). Clearly some of these options are achieving greater levels ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by ...
January 2018
-
NPS+ Hepatitis C Virus (HCV)Infection (EU5) [2018]
US$ 2,655.00
... infectious diseases specialists and primary care physicians (PCPs) treating hepatitis C virus infection (HCV). Clearly some of these options are achieving greater levels of ... higher the score the healthier the brand. What is FirstView NPS+? NPS+ turns your Net Promoter Score into actionable information by ...
January 2018
-
Chronic lymphocytic leukemia (CLL): Update Bulletin #2
US$ 1,095.00
... key opinion leader (KOL) views on recent developments in the chronic lymphocytic leukaemia (CLL) market. Topics covered include: full results from the Phase ... Imbruvica (ibrutinib; Janssen Biotech/AbbVie) in patients with high-risk CLL. Business Questions: In light of the positive results for Venclexta/Rituxan ...
January 2018
-
Malignant Melanoma: Update Bulletin
US$ 1,095.00
... ipilimumab for the treatment of patients with anti-PD-1 refractory metastatic melanoma; and views on the results of a Phase II study investigating ... Iovance Biotherapeutics’ LN-144 for the treatment of metastatic melanoma. Business Questions: Do KOLs anticipate the results of the EORTC1325/ ...
January 2018
-
Market Access Impact: Ulcerative Colitis (EU5) 2018
US$ 5,345.00
... (golimumab; Merck Sharp & Dohme) Exploring Important Market Access Issues Market Access Impact: Ulcerative Colitis (EU5) explores key issues affecting Ulcerative Colitis drug manufacturers. You’ll learn: How barriers ...
January 2018
-
Market Access Impact: Ulcerative Colitis (US) 2018
US$ 5,345.00
... your brand can do to level the playing field in Market Access Impact: Ulcerative Colitis (US) [2018]. Based on a survey of 100 ... Janssen Biotech) Exploring Market Access Barriers Market Access Impact: Ulcerative Colitis (US) [2018] explores key issues affecting Ulcerative Colitis drug manufacturers. You’ll ...
January 2018
-
Non Small Cell Lung Cancer (NSCLC): Update Bulletin #2
US$ 1,095.00
... presents key opinion leader (KOL) views on recent developments in the non-small cell lung cancer (NSCLC) market. Topics covered include: the success of the Phase ... Avastin (bevacizumab) plus chemotherapy in the first-line treatment of advanced non-squamous NSCLC at the ESMO Immuno Oncology Congress 2017; Bristol ...
January 2018
-
Nonalcoholic Steatohepatitis (NASH): Update Bulletin
US$ 1,095.00
... (KOLs) from North America and Europe on a variety of recent events in NASH market, including; Intercept Pharmaceuticals announcing the initiation of the global ... do KOLs say? How do KOLs arte the development of elafibranor in paediatric NASH? What concerns do experts have with elafibranor in children? What are ...
January 2018
-
NPS+ Haemophilia B (EU5) 2018
US$ 2,655.00
... leading brands compare to its competitors? NPS+ Haemophilia B (EU5) gives a unique insight into the ... the pack. In Europe, 2 of the 6 brands surveyed obtained a positive NPS, with one brand ... conducted the survey between February 6-19, 2018. What is Net Promoter® Score? NPS is a customer loyalty metric developed ...
January 2018
-
NPS+ Haemophilia B (US) 2018
US$ 2,655.00
... ‘useful but very expensive’? Explore Important Brand Loyalty Issues NPS+ Haemophilia B (US) offers valuable insight into brand loyalty from the ... in the world. We conducted the survey between February 6-19, 2018. What is Net Promoter® Score? NPS is a customer loyalty metric developed by (and a registered ...
January 2018
-
Systemic Lupus Erythematosus (SLE): Update Bulletin #2
US$ 1,095.00
... leader (KOL) insights on the latest events happening in Systemic Lupus Erythematosus (SLE) treatment landscape. Topics covered include expert opinions on the ... study investigating Stelara (ustekinumab; Janssen Biotech) for the treatment of SLE, and the potential for XTL Biopharmaceuticals’ edratide as well as ...
January 2018
-
